Fulcrum Therapeutics Inc

NASDAQ:FULC  
13.81
+0.02 (+0.14%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)443.15M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.63 Million
Adjusted EPS-$0.72
See more estimates
10-Day MA$12.79
50-Day MA$12.19
200-Day MA$13.03
See more pivots

Fulcrum Therapeutics, Inc. Stock, NASDAQ:FULC

26 LANDSDOWNE STREET, CAMBRIDGE, MA 02139
United States of America
Phone: 617-651-8851
Number of Employees:

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.